ProSolus Makes a Mark in Miami's Pharmaceutical Industry

Online, June 26, 2013 (Newswire.com) - ProSolus Pharma focuses on transdermal technology for delivery pharmaceutical products safely through the skin, providing steady blood levels and avoiding medicinal highs/lows. The resulting products are less likely to be abused, or to interact negatively with other medications in the body. ProSolus' transdermal formulation can be used for a variety of therapeutic categories, creating options for non-irritant, reliable, and discrete drug delivery for many conditions.

ProSolus was originally incorporated in Philadelphia, Pennsylvania, and moved to Miami, Florida in early 2011. That same year, ProSolus began the planning and building their own cGMP manufacturing facility. The construction of the new state-of-the-art facility was completed in 2012, and manufacturing begun.

The completion of two pilot clinical trials in the first quarter of 2013 marks a large pharmaceutical achievement; ProSolus was GMP compliant just one year from commencement, and able to use materials manufactured in-house.

Though the ProSolus facility is new to South Florida, the company has already been nominated by the Beacon Council as Company of the Year in the pharmaceutical category. ProSolus was also one of 30 companies to receive the "Key to the City" of Miami Dade County in 2011. ProSolus is also currently nominated for the 2012 Governor's "Innovators in Business" awards, for their contribution to the local economy and that of the state of Florida.

Press opportunities can be scheduled through ProSolus' marketing affiliate, Pulley Media, at [email protected].

Follow Prosolus on Twitter or Facebook for breaking news, employment opportunities, and pharmaceutical headlines.

For more details visit on : http://www.prosoluspharma.com